David E Spaner
Overview
Explore the profile of David E Spaner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
2342
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luo Y, Su B, Hung V, Luo Y, Shi Y, Wang G, et al.
Proc Natl Acad Sci U S A
. 2024 Aug;
121(33):e2405644121.
PMID: 39121163
Nuclear factor kappa B (NFκB) is a pathogenic factor in chronic lymphocytic leukemia (CLL) that is not addressed specifically by current therapies. NFκB is activated by inflammatory factors that stimulate...
2.
Spaner D, Luo T, Wang G, Schreiber G, Harari D, Shi Y
Front Oncol
. 2023 Apr;
13:1043694.
PMID: 37114129
Introduction: Chronic lymphocytic leukemia (CLL) is characterized by an aberrant cytokine network that can support tumor growth by triggering janus kinase (JAK)/STAT pathways. Targeting cytokine-signaling should then be a rational...
3.
Luo T, Shi Y, Wang G, Spaner D
J Immunol
. 2022 Sep;
209(9):1662-1673.
PMID: 36104109
Type I IFN is made by cells in response to stress. Cancer cells exist in a state of stress, but their IFN response is complex and not completely understood. This...
4.
Spaner D
Front Immunol
. 2021 Dec;
12:772304.
PMID: 34868034
In the past decade, aberrant O-GlcNAcylation has emerged as a new hallmark of cancer. O-GlcNAcylation is a post-translational modification that results when the amino-sugar β-D-N-acetylglucosamine (GlcNAc) is made in the...
5.
Spaner D, Luo Y, Wang G, Gallagher J, Tsui H, Shi Y
Cancer Med
. 2021 Nov;
10(24):8789-8798.
PMID: 34791813
Preclinical observations that killing of chronic lymphocytic leukemia (CLL) cells was dexamethasone (DEX) were enhanced by concomitant inhibition of Bruton's tyrosine kinase and janus kinases (JAKs) motivated a phase II...
6.
Xia M, Luo T, Shi Y, Wang G, Tsui H, Harari D, et al.
J Immunol
. 2020 Oct;
205(10):2629-2639.
PMID: 33067379
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has profound activity in chronic lymphocytic leukemia (CLL) but limited curative potential by itself. Residual signaling pathways that maintain survival of CLL cells...
7.
Spaner D, McCaw L, Wang G, Tsui H, Shi Y
Cancer Med
. 2019 Mar;
8(4):1540-1550.
PMID: 30843659
Methods to deepen clinical responses to ibrutinib are needed to improve outcomes for patients with chronic lymphocytic leukemia (CLL). This study aimed to determine the safety and efficacy of combining...
8.
Liu T, Xia L, Yao Y, Yan C, Fan Y, Gajendran B, et al.
Cell Death Dis
. 2019 Feb;
10(2):117.
PMID: 30741932
The ETS transcription factor Fli-1 controls the expression of genes involved in hematopoiesis including cell proliferation, survival, and differentiation. Dysregulation of Fli-1 induces hematopoietic and solid tumors, rendering it an...
9.
Shi Y, Wang G, Muhowski E, McCaw L, Wang C, Bjarnason G, et al.
Leukemia
. 2019 Jan;
33(7):1650-1662.
PMID: 30696950
Glucocorticoid (GC) receptor (GR) phosphorylation and signature genes were studied in chronic lymphocytic leukemia (CLL) cells to help place GCs within modern treatment algorithms. In contrast to normal B and...
10.
Spaner D, Venema R, Huang J, Norris P, Lazarus A, Wang G, et al.
EBioMedicine
. 2018 Sep;
35:222-232.
PMID: 30174282
The intrinsic humoral immunodeficiency of chronic lymphocytic leukemia (CLL) is often managed with immunoglobulin replacement therapy (IgRT) to maintain IgG levels in the low-normal range (6-8 g/L) but optimal targets...